Introduction
============

Marfan syndrome (MFS) is a connective tissue disorder with autosomal dominant inheritance that is caused by mutation in the fibrillin-1 (*FBN1*) gene.[@B1][@B2] The clinical spectrum of MFS is highly variable, even within an affected family, and shows multiorgan involvement affecting the skeleton, the cardiovascular system, the eyes, the lungs, and the skin. Cardiovascular involvement is the most common cause of morbidity and mortality in MFS.[@B3]

The diagnosis of MFS has depended on the revised Ghent nosology, which is based on data obtained from predominantly Western populations.[@B4] Possible ethnic differences in the clinical manifestations of patients with MFS have been suggested.[@B5] However, there are limited data available on the clinical features of Korean patients with MFS, and the available reports are based on only small numbers of patients.[@B5][@B6] Therefore, the aim of the present study was to describe the clinical characteristics and outcomes of Korean patients with MFS.

Subjects and Methods
====================

Patients
--------

We identified all patients who were diagnosed with MFS between January 1995 and May 2015 in the Marfan Clinic at a single tertiary medical center. We screened 409 patients. Patients who were diagnosed with MFS-related disorders including MASS phenotype (myopia, mitral valve prolapse, borderline and non-progressive aortic root dilatation, skeletal findings, and striae), mitral valve prolapse syndrome (MVPS), and ectopia lentis syndrome (ELS) were excluded. Among patients with possible MFS, those who did not satisfy the revised Ghent nosology because of insufficient evaluation for MFS were also excluded.[@B4] In addition, patients aged \<20 years who had insufficient systemic features and borderline aortic root dilatation indicating potential MFS were excluded. Finally, a total of 343 Korean patients aged ≥15 years who satisfied the revised Ghent nosology were included.

Data collection
---------------

The multidisciplinary data including physical examination, computed tomography (CT) angiography, transthoracic echocardiography, slitlamp examination, and genetic analysis were collected retrospectively from the medical records. We measured the aortic diameter at the level of the sinus of Valsalva on at least two images from transthoracic echocardiography.[@B7] If transthoracic echocardiographic imaging before aortic surgery or aortic dissection was not available, we measured the diameter at the level of the sinus of Valsalva on CT angiography.[@B8] The Z-score was calculated on the basis of aortic diameter with age and body surface area (BSA).[@B9] The descending aorta was considered to be an aneurysm if any diameter of the aorta was greater than 35 mm without aortic dissection.[@B8] Ectopia lentis was diagnosed by an ophthalmologist using slit lamp examination. In addition, patients were regarded as having ectopia lentis if they had a history of previous eye surgery for lens dislocation. Myopia was defined as a spherical equivalent less than -3.0 diopters. An *FBN1* gene mutation was defined as positivity for the mutation known to be associated with aortic root aneurysm/dissection.[@B4] Extended physical examination was performed by medical specialists. Protrusio acetabuli was defined as medial displacement of the acetabulum on axial CT images.[@B7][@B10] We obtained death registry data from the National Statistical Office of South Korea.

Statistical analysis
--------------------

Continuous variables are presented as mean±one standard deviation, and categorical variables as numbers and percentages. Data analysis was performed using SPSS version 21 (IBM, Armonk, NY, USA). This study was approved by the institutional review board of Samsung Medical Center.

Results
=======

A total of 343 patients with MFS and 218 probands were identified. Median follow-up duration was 52.8 months (range 0.0 to 233.9 months). The mean patient age at diagnosis was 35.9±12.6 years and 172 patients (50.1%) were male. Mean height was 184.4±10.0 cm for male patients and 170.5±7.7 cm for females. Beta-blockers were used in 96.8% of patients with MFS and angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) were used in 68.8% of them during the last 3 years of follow-up. The clinical characteristics of the patients with MFS are described in [Table 1](#T1){ref-type="table"}.

In the systemic features, facial features (231 patients, 75.2%), wrist and thumb sign (216 patients, 71.1%), myopia (162 patients, 70.4%), skin striae (69.8%), protrusio acetabuli (205 patients, 64.3%), and dural ectasia (196 patients, 61.8%) were common. In contrast, skeletal manifestations including pectus carinatum deformity (27 patients, 8.2%), pectus excavatum or chest asymmetry (50 patients, 15.2%), increased arm/height (45 patients, 15.0%), and reduced elbow extension (55 patients, 17.5%) were rarely detected.

The components of revised Ghent nosology in patients with MFS are shown in [Table 2](#T2){ref-type="table"}. A total of 303 patients (88.6%) had aortic root dilatation with Z score ≥2 or aortic root dissection. Ectopia lentis was relatively less common (163 patients, 55.1%) and systemic score ≥7 was found in 217 patients (73.8%). Among 218 probands, 121 patients (55.5%) were identified as sporadic cases and 97 patients (44.5%) had a family history. Among the 157 probands who underwent genetic analysis, 141 (89.8%) patients had an *FBN1* mutation associated with aortic root aneurysm/dissection.

Clinical outcomes of Korean patients with MFS are shown in [Table 3](#T3){ref-type="table"}. Of a total of 343 patients, aortic dissection (AD) or intramural hematoma (IMH) was identified in 110 patients (32.1%). Among the 110 patients with AD or IMH, AD was detected in 106 patients (96.3%), including 2 patients with a mixed type of AD and IMH, and IMH was present in only 4 patients (3.6%). Of the 106 patients with AD, 70 (66.0%) had type A AD and 36 (34.0%) had Type B AD. Data on aortic diameter of sinus of Valsalva at the time of AD was available in 40 patients and was 6.29±1.19 cm (range 3.4 to 9.3 cm) in patients with Type A AD. Two patients experienced Type A AD with aortic diameter at the level of sinus of Valsalva less than 4.5 cm. Among the 36 patients with type B AD, maximal diameter of the descending aorta at the time of diagnosis with type B AD was 4.51±1.66 cm (range 2.64 to 8.4 cm) in 31 patients for whom data were available.

Among the 221 patients who did not have AD or IMH, descending aortic aneurysm was identified in 19 patients (8.6%); thoracic aortic aneurysm in 3 patients (15.8%), thoracoabdominal aortic aneurysm in 6 patients (31.6%), and abdominal aortic aneurysm in 10 patients (52.6%). Of a total of 343 patients, 213 patients underwent cardiovascular surgery of any type. Patients\' age at the time of initial cardiovascular surgery was 35.5±11.3 years (range 6.3-69.6 years). Eight patients died during follow-up.

Discussion
==========

In the present study we documented the clinical characteristics of a large number of Korean patients with MFS. The majority of Korean MFS patients had cardiovascular manifestations, especially ascending aorta dilatation/dissection, and an *FBN1* mutation. Systemic score ≥7 was identified in approximately two-thirds of all patients. In contrast, ectopia lentis and a family history of MFS were relatively uncommon findings that were documented in about half of our MFS patients.

The mortality rate in patients with MFS is 20-40 times higher than in normal individuals of the same age.[@B11] The clinical manifestations of patients with MFS are highly variable. As more than two-thirds of our Korean patients with MFS showed characteristic wrist and/or thumb sign, facial features, and skin striae, we suggest that careful physical examination is extremely important for the diagnosis of MFS. In addition, we identified that dural ectasia and protrusio acetabuli were also common findings. In the process of evaluation of aortic dissection, inspective review of CT angiography could be critical in diagnosing MFS, especially for young patients without risk factors such as hypertension, because sufficient data for the diagnosis of MFS might be obtained by CT angiography.[@B12]

Among patients with MFS, possible ethnic differences in clinical manifestations between Asian and Western populations were reported.[@B13] Akutsu et al.[@B13] showed that Japanese patients with MFS had less common skeletal involvement as compared with Western patients. This is consistent with our findings in Korean patients with MFS. We identified increased arm/height in 15% and scoliosis in 19% of our patients, compared with 55% and 53% of Western patients with MFS, respectively.[@B14] In addition, Korean patients with MFS had shorter height, lower body weight, and lower body surface area in comparison with Western patients.[@B15]

We identified more common cardiovascular involvement that included aortic root dilatation of Z score ≥2 or aortic root dissection in 88%, any aortic dissection or IMH in 32%, and Type A AD in 20% of our Korean patients with MFS, compared with corresponding values of 77%, 21% and 14% among Western patients, respectively.[@B14] In addition, more than 60% of our patients had some form of cardiovascular surgery, even though their mean age was only 35.9 years. The most common cause of death in MFS is a cardiovascular manifestation such as aortic dissection, congestive heart failure, or valvular heart disease.[@B2] Cardiovascular involvement might manifest more commonly in Asian patients than in Western patients.[@B13][@B14][@B15] Therefore, we suggest that more careful evaluation and follow-up for cardiovascular involvement might be needed in Korean patients with MFS.

With respect to ocular manifestations, ectopia lentis was present in 54.6% of Korean patients in the present study. In earlier studies, Asian patients with MFS had a lower occurrence of ectopia lentis (25-36%) as compared with Western patients (54%).[@B5][@B13][@B14][@B15] However, the results of previous studies might have shown selection bias because of the small numbers of patients involved. We identified that Korean patients with MFS had a comparable incidence of ocular manifestation including ectopia lentis and myopia, although ocular manifestation was relatively less frequent than other organ involvement. Nonetheless, considering the cardiovascular and skeletal manifestations, ethnic differences of clinical features in MFS patients are possible.

If patients have a family history of MFS, diagnosis can be made with comparative ease based on the revised Ghent nosology when the patients have any manifestations among ectopia lentis, systemic score ≥7, and aortic dilatation with Z score ≥2 or aortic root dissection. In contrast, for patients without family history of MFS, the diagnosis of MFS should depend on an aortic dilatation with Z score ≥2 or aortic root dissection, except for patients with concurrent ectopia lentis and an *FBN1* mutation of known association with aortic root aneurysm/dissection. Therefore, the diagnosis of MFS might be delayed until significant aortic root dilatation with Z score ≥2 or aortic dissection has developed. In Korea, the diagnosis of genetic disorders is particularly difficult because patients tended to be reluctant to undergo genetic screening, although this situation has recently improved. Moreover, probands with a family history were only 45.5% of cases in this study. A cohort of Korean patients with MFS might consist mainly of patients diagnosed by cardiovascular events such as aortic dissection rather than asymptomatic patients diagnosed by family screening. In this regard, the rate of cardiovascular manifestations in Korean patients with MFS might be overestimated. Therefore, early detection of asymptomatic patients in Korea through active genetic screening of MFS-affected families would be critical.

The present study has several limitations. Because of its retrospective design, data collection based on medical records was limited. In addition, this study might have a selection bias. Because our center was a tertiary referral center, we could not obtain sufficient data for long-term clinical outcomes. Nevertheless, we described the clinical characteristics and outcomes during a median follow-up duration of 52.8 months.

In conclusion, we described the clinical characteristics and outcomes of Korean patients with MFS. Cardiovascular manifestations were commonly detected and an *FBN1* gene mutation was present in approximately 90% of patients. In contrast, ectopia lentis was identified in approximately half of our patients. To the best of our knowledge, the current study reports on clinical characteristics based on the largest numbers of Korean MFS patients studied to date. Our findings will be informative for the evaluation of patients with MFS.
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###### Clinical characteristics of patients with MFS

![](kcj-46-841-i001)

                                        Values
  ------------------------------------- ------------
  Age at diagnosis (years)              35.9±12.6
  Age at last follow-up (years)         39.8±12.5
  Male                                  172 (50.1)
  Height (cm)                           177.5±11.3
   Male                                 184.4±10.0
   Female                               170.5±7.7
  Weight (kg)                           66.3±15.1
  Body mass index (kg/m^2^)             20.9±3.5
  Wrist and thumb sign                  216 (71.1)
  Wrist or thumb sign                   7 (2.3)
  Pectus carinatum deformity            27 (8.2)
  Pectus excavatum or chest asymmetry   50 (15.2)
  Hindfoot deformity                    8 (2.6)
  Plain pes planus                      170 (55.6)
  Protrusio acetabuli                   205 (64.3)
  Increased arm/height                  45 (15.0)
  Scoliosis or thoracolumbar kyphosis   62 (19.1)
  Reduced elbow extension               53 (17.5)
  Facial features (3/5)                 231 (75.2)
  Pneumothorax                          57 (17.9)
  Skin striae                           213 (69.8)
  Myopia                                162 (70.4)
  Mitral valve prolapse (all types)     95 (29.3)
  Dural ectasia                         196 (61.8)

Continuous variables are presented as mean±one standard deviation, and categorical variables as numbers and percentages. MFS: Marfan syndrome

###### Components of the revised Ghent nosology in patients with MFS
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                          Events/available data   \%
  ----------------------- ----------------------- ------
  Ao (Z score ≥2)         303/342                 88.6
  Ectopia lentis          163/296                 55.1
  *FBN1* gene mutation    141/157^\*^             89.8
  Systemic score ≥7       217/294                 73.8
  Family history of MFS   97/218                  44.5

^\*^Number of available data among the probands. ^†^Number of probands. MFS: Marfan syndrome, Ao: aortic diameter at the sinus of Valsalva above indicated Z-score or aortic root dissection, *FBN1*: Fibrillin-1

###### Clinical outcomes of patients with MFS

![](kcj-46-841-i003)

                                                                             Events/total number              \%
  -------------------------------------------------------------------------- -------------------------------- ------
  AD/IMH                                                                     110/343                          32.1
   AD                                                                        106/110                          96.4
    Type A AD                                                                70/106                           66.0
    Aortic diameter at the sinus of Valsalva at the time of type A AD (cm)   6.29±1.19^\*^ (range 3.4--9.3)   
    Type B AD                                                                36/106                           34.0
    Maximal diameter of descending aorta at the time of type B AD (cm)       4.51±1.66^†^ (range 2.6--8.4)    
   IMH                                                                       4/110                            3.6
  Any descending aorta aneurysm                                              19/221                           8.6
    Thoracic aorta aneurysm                                                  3/19                             15.8
    Thoraco-abdominal aorta aneurysm                                         6/19                             31.6
    Abdominal aorta aneurysm                                                 10/19                            52.6
  Any cardiovascular surgery                                                 213/343                          62.1
  All-cause death                                                            8/343                            0.02

^\*^Values are presented as mean±standard deviation and available for 40 (57.1%) patients. ^†^Values are presented as mean±standard deviation and available for 31 (86.1%) patients. MFS: Marfan syndrome, AD: aortic dissection, IMH: intramural hematoma
